All filters
Slidesets
Getting involved in clinical research: from clinical trials to sub-studies- Nicholas Paton, MD, FRCP
Presented at:
APACC 2018
Slidesets
How to do a systematic review- Matthew Law, BA (Hons), MSc, PhD & Joseph Tucker, MD, PhD, AM
Presented at:
APACC 2018
Slidesets
The HIV epidemic in CEE countries- Oana Săndulescu, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
How would the epidemic evolve in the future- David van de Vijver
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Long acting HIV drugs for prevention: what are the data?- Pep Coll, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
HIV transmission in the migrant population- Dimitrios Paraskevis, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Is there a need for HCV resistance testing in routine diagnostics and patient treatment? - Routine HCV genotyping and resistance testing and performance of the Sentosa SQ HCV Genotyping v2.0 assaysing next-generation sequencing- Robert Ehret
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
The prevalence of resistance associated substitutes through Europe The European prevalence of hepatitis C virus NS5A polymorphisms- Stephanie Popping
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
The current status of PrEP in Europe- Pep Coll, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Influence of resistance in the future- Richard Harrigan, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
A 5 amino-acid insertion in the C-terminal region of HIV-2 integrase impacts phenotypic susceptibility to the five integrase inhibitors- Quentin Le Hingrat
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
A new wild-type HIV in the era of transmitted drug resistance- Kristof Theys, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort- Francesca Lombardi
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study- Alexander Thielen
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings- Maria Santoro
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Mutations in the 3’-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo- Jeroen van Kampen
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Novel simplified bioinformatics for NGS data analysis- Marc Noguera-Julian, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Management of hepatitis C therapy failures - clinical perspective- Sanjay Bhagani, BSc FRCP
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Management of hepatitis C therapy failures - virological perspective- Francesca Ceccherini– Silberstein, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics- Slim Fourati
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia
Presented at:
European Meeting on HIV & Hepatitis 2018